Innovent's weight-loss drug highlights China challenge for Novo, Lilly

Innovent Biologics has launched its GLP-1 weight-loss drug, Xinermei (mazdutide), in China, intensifying competition against Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in a market projected to be worth billions. Leveraging a local-centric marketing strategy and highlighting Xinermei's unique liver fat reduction benefit, Innovent has seen its shares surge 155% year-to-date. Morningstar projects Xinermei to generate over 600 million yuan ($84.4 million) this year, peaking at 3.5 billion yuan in 2029, while Novo's Wegovy sales in China are estimated at $346 million this year, facing potential decline post-2026 patent expiry and increased competition from both Innovent and impending generics.

Analysis

Innovent Biologics (1801.HK) is rapidly gaining traction in China's burgeoning GLP-1 weight-loss market with its newly launched drug, Xinermei (mazdutide), presenting a formidable challenge to Western incumbents Novo Nordisk (NVO) and Eli Lilly (LLY). The company's strategy leverages a deep understanding of the local market, aggressive expansion through online platforms and private clinics, and a key clinical differentiator: Xinermei's proven ability to reduce liver fat, a feature that is resonating with physicians. This successful entry is reflected in Innovent's stock performance, which has surged 155% year-to-date, in stark contrast to Novo's 38% decline and Lilly's 3% drop. Financially, Morningstar projects Xinermei will generate over 600 million yuan ($84.4 million) in its first year, with peak sales reaching 3.5 billion yuan by 2029. This momentum coincides with significant headwinds for Novo Nordisk, whose obesity care sales in China fell sharply from 704 million to 158 million Danish crowns quarter-over-quarter. Furthermore, Innovent's drug has just received approval for type 2 diabetes, expanding its addressable market. However, the entire sector faces a critical inflection point, as Novo's patent on Wegovy's active ingredient expires in China in 2026, which is expected to usher in an era of intense generic competition that could pressure pricing and margins for all branded players.

Key Decisions for Investors

• Investors should recognize Innovent Biologics (1801.HK) as a strong regional competitor with significant upside, buoyed by Xinermei's successful launch, differentiated product profile, and expanded approval for diabetes, though its 155% stock rally suggests high expectations are already priced in.
• Holders of Novo Nordisk (NVO) must closely monitor its China operations, as the combination of a sharp Q2 sales decline, intensifying competition from Xinermei, and the looming 2026 patent cliff for semaglutide presents a material risk to its regional market share and profitability.
• Eli Lilly's (LLY) exposure to the Chinese GLP-1 market is complex; while its drug Mounjaro faces direct competition, the company's licensing of mazdutide to Innovent provides a partial hedge and a stake in a successful local product.
• Long-term investors across the entire GLP-1 space should model for significant margin compression in China beginning in 2026-2027, as the anticipated launch of generic semaglutide will fundamentally alter the competitive and pricing landscape.